Cryo-Cell (CCEL) CIO granted new performance-based stock options

Rhea-AI Filing Summary

Cryo-Cell International's Chief Information Officer, Oleg Mikulinsky, reported new equity awards and existing holdings. On January 7, 2026, he received two grants of stock options on the company’s common stock at an exercise price of $3.54 per share, one for 10,000 options that vest in thirds on January 7, 2026, 2027 and 2028, and another for 20,000 options granted under the Cryo-Cell 2022 Stock Incentive Plan with three tranches tied to both time and stock-price performance hurdles at $6, $8, and $10 per share over specified 20-day periods. He also reports direct ownership of 104,349 common shares and several prior option awards with varying exercise prices and vesting schedules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mikulinsky Oleg

(Last) (First) (Middle)

700 BROOKER CREEK BLVD

SUITE 1800

(Street)

OLDSMAR FL 34677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRYO CELL INTERNATIONAL INC [ CCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Information Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								104,349	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$7.49							05/21/2018	05/21/2028	Common Stock	8,000		8,000	D
Stock Option	$7.13							09/04/2019	09/04/2029	Common Stock	4,444		4,444	D
Stock Option	$6.55							02/27/2020	02/27/2030	Common Stock	1,333		1,333	D
Stock Option	$8							09/23/2021(1)	09/23/2028	Common Stock	10,000		10,000	D
Stock Option	$11.9							12/28/2021(2)	12/28/2028	Common Stock	20,000		20,000	D
Stock Option	$5.88							12/22/2023(3)	12/22/2028	Common Stock	10,000		10,000	D
Stock Option	$7.35							01/21/2025(4)	01/21/2030	Common Stock	10,000		10,000	D
Stock Option	$3.54	01/07/2026		A		10,000		01/07/2026(5)	01/07/2031	Common Stock	10,000	$3.54	10,000	D
Stock Option	$3.54	01/07/2026		A		20,000		01/07/2026(6)	01/07/2031	Common Stock	20,000	$3.54	20,000	D

Explanation of Responses:

1. Stock options vest 1/5 per year commencing on September 23, 2021.

2. Stock options vest immediately if the price of the Company's stock reaches $25.00 per share during the seven year option period.

3. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.

4. Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.

5. Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.

6. The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.

	/s/ Oleg Mikulinsky	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Cryo-Cell (CCEL) report for Oleg Mikulinsky?

The filing shows that Chief Information Officer Oleg Mikulinsky reported new stock option grants on January 7, 2026, along with his existing common stock and option holdings.

How many new stock options did the Cryo-Cell CIO receive on January 7, 2026?

He received two new stock option grants: one for 10,000 options and another for 20,000 options, each with an exercise price of $3.54 per share.

What are the vesting terms for the 10,000 Cryo-Cell options granted at $3.54?

The 10,000 options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028, subject to continued service.

What performance conditions apply to the 20,000 Cryo-Cell options granted at $3.54?

The 20,000 options are split into three equal tranches that each require both time-based vesting and the stock achieving an average closing price of at least $6, $8, or $10 per share over 20 consecutive trading days, in addition to continued service.

How many Cryo-Cell common shares does the CIO beneficially own after these transactions?

Following the reported transactions, he directly beneficially owns 104,349 shares of Cryo-Cell common stock.

What existing Cryo-Cell stock option awards does the CIO hold besides the new grants?

He holds several earlier stock option awards on common stock with exercise prices including $7.49, $7.13, $6.55, $8, $11.90, $5.88, and $7.35, each with its own vesting schedule and expiration date.